Neon Therapeutics, Inc. (NTGN)

Notice is hereby given that Faruqi & Faruqi, LLP has filed a class action lawsuit in the United States District Court for the Southern District of New York, Case No. 1:20-cv-03033 on behalf of shareholders of Neon Therapeutics, Inc. (“Neon” or the “Company”) (NASDAQ:NTGN) who have been harmed by Neon’s and its board of directors’ (the “Board”) alleged violations of Sections 14(a) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”) in connection with the proposed merger of the Company with BioNTech SE (the “Proposed Transaction”). 

On January 15, 2020, the Board caused the Company to enter into an agreement and plan of merger under which Neon shareholders stand to receive 0.063 American Depositary Shares of BioNTech for each share of Neon stock they own.

The complaint alleges that the Form F-4 Registration Statement filed with the Securities and Exchange Commission violates Sections 14(a) and 20(a) of the Exchange Act because it provides materially incomplete and misleading information about the Company and the Proposed Transaction, including information concerning the Company’s financial projections and analysis, on which the Board relied to recommend the Proposed Transaction as fair to Neon shareholders. 

If you wish to serve as lead plaintiff, you must move the Court no later than June 23, 2020.  Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member.

If you wish to obtain information concerning this action, you can do so by filling out the form below